©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2025; 31(40): 111775
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111775
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111775
Imaging monitoring contributes to the “treat-to-target” strategy in the management of Crohn’s disease
Jia-Yi Yang, Department of Radiology, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
Shan-Shan Wu, Department of Gastroenterology and Hepatology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China
Co-first authors: Jia-Yi Yang and Shan-Shan Wu.
Author contributions: Yang JY wrote the letter; Yang JY and Wu SS collected the literatures, and made equal contributions as co-first authors; both authors have read and approved the final version to be published.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Jia-Yi Yang, Department of Radiology, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, No. 299 Qingyang Road, Wuxi 214023, Jiangsu Province, China. yangjy2150@163.com
Received: July 9, 2025
Revised: August 4, 2025
Accepted: September 24, 2025
Published online: October 28, 2025
Processing time: 110 Days and 18 Hours
Revised: August 4, 2025
Accepted: September 24, 2025
Published online: October 28, 2025
Processing time: 110 Days and 18 Hours
Core Tip
Core Tip: Crohn’s disease (CD) is a chronic relapsing inflammatory bowel disorder characterized by transmural inflammation. Mucosal healing assessed by endoscopy remains the gold standard criterion for determining the therapeutic endpoint. However, transmural healing, evaluated via cross-sectional imaging techniques, is associated with superior long-term outcomes compared with mucosal healing and has consequently been proposed as a more suitable treatment goal in CD. Recent advances in radiomics can be used to extract hidden biological signatures from cross-sectional imaging and offer novel approaches for the diagnosis, monitoring, and prognostic assessment of CD, thereby offering patients more personalized medicine.